According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...
Pachydrusen-associated AMD may progress slower than typical AMD. Age and macular pigment changes increase the risk of complications. Current AMD risk models may not apply to eyes with pachydrusen. AMD ...
Sanaregen Vision Therapeutics Inc. has received FDA clearance to conduct a phase I/II trial of SVT-001, an investigational cell therapy for individuals with familial drusen.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results